COVID-19 and influenza often co-circulate in the community. It is important to protect those at higher risk of severe disease, including residents of residential aged care homes (RACHs).
NSW Health is working with general practitioners (GPs) and aged care providers to make sure residents have a plan in place in case they develop symptoms of COVID-19 or influenza; including a plan for testing and a discussion about antiviral medicines.
A Pre-assessment action plan for respiratory infections in aged care home residents is available to facilitate timely access of antiviral medicines for residents if they test positive to COVID-19, or test positive or are exposed to influenza.
The administration of antiviral medicine soon after symptom onset for people with COVID-19 or influenza can reduce disease severity.
Nirmatrelvir/ritonavir and molnupiravir are available on the Pharmaceutical Benefits Scheme (PBS) for residents of RACHs through community pharmacies for treatment of COVID-19. Oseltamivir is available as outlined below or on private prescription.
Aged care homes can order Oseltamivir (Tamiflu®) directly from the State Vaccine Centre by completing the online RACH influenza antiviral treatment access form.
Once the form is complete, the request will go to the NSW vaccine distribution warehouse to be filled and distributed. Aged care homes can only order up to 250 doses of oseltamivir using this form. For orders over 250 doses, aged care homes will need to contact their local public health unit on 1300 066 055.
These resources have been developed to guide discussions between residents and their families with their GP regarding the use of antiviral medicines:
For additional information on holding antivirals at residential facilities, see the Requirements for residential care facilities (RCFs) under the NSW Poisons and Therapeutic Goods Legislation.